CN103037869A - 治疗炎症的方法 - Google Patents

治疗炎症的方法 Download PDF

Info

Publication number
CN103037869A
CN103037869A CN201180027139XA CN201180027139A CN103037869A CN 103037869 A CN103037869 A CN 103037869A CN 201180027139X A CN201180027139X A CN 201180027139XA CN 201180027139 A CN201180027139 A CN 201180027139A CN 103037869 A CN103037869 A CN 103037869A
Authority
CN
China
Prior art keywords
polymer
biocompatible polymer
dipentaerythritol
pentaerythritol
sorbent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180027139XA
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·P·哈恩
韦伊-塔伊·扬
文森特·J·卡波尼
托马斯·D·戈洛比什
罗伯特·H·巴特利特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytosorbents Corp
Original Assignee
Cytosorbents Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosorbents Corp filed Critical Cytosorbents Corp
Priority to CN201710354912.2A priority Critical patent/CN107260755A/zh
Publication of CN103037869A publication Critical patent/CN103037869A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004—Sorbent size or size distribution, e.g. particle size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28073—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being in the range 0.5-1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28076—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being more than 1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/305—Addition of material, later completely removed, e.g. as result of heat treatment, leaching or washing, e.g. for forming pores
    • B01J20/3064—Addition of pore forming agents, e.g. pore inducing or porogenic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2201/00—Foams characterised by the foaming process
    • C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
    • C08J2201/044—Elimination of an inorganic solid phase
    • C08J2201/0444—Salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00—Foams characterised by their intended use
    • C08J2207/10—Medical applications, e.g. biocompatible scaffolds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
    • C08J2325/02—Homopolymers or copolymers of hydrocarbons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180027139XA 2010-04-01 2011-04-01 治疗炎症的方法 Pending CN103037869A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710354912.2A CN107260755A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31999310P 2010-04-01 2010-04-01
US61/319,993 2010-04-01
PCT/US2011/030919 WO2011123767A1 (en) 2010-04-01 2011-04-01 Method of treating inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710354912.2A Division CN107260755A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Publications (1)

Publication Number Publication Date
CN103037869A true CN103037869A (zh) 2013-04-10

Family

ID=44712650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180027139XA Pending CN103037869A (zh) 2010-04-01 2011-04-01 治疗炎症的方法
CN201710354912.2A Pending CN107260755A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710354912.2A Pending CN107260755A (zh) 2010-04-01 2011-04-01 治疗炎症的方法

Country Status (9)

Country Link
US (6) US9717755B2 (https=)
EP (2) EP2552459B1 (https=)
JP (2) JP6073778B2 (https=)
CN (2) CN103037869A (https=)
AU (1) AU2011234978B2 (https=)
CA (1) CA2795177C (https=)
ES (1) ES2686545T3 (https=)
MX (1) MX342421B (https=)
WO (1) WO2011123767A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794197A (zh) * 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
CN110662590A (zh) * 2017-05-23 2020-01-07 西托索尔本茨公司 治疗创伤性脑损伤的方法
CN113365642A (zh) * 2018-11-16 2021-09-07 希玛奈克斯特股份有限公司 用于控制炎症患者中不良事件的方法
CN115768459A (zh) * 2020-04-14 2023-03-07 西托索尔本茨公司 通过免疫调节治疗改善免疫应答和减少免疫麻痹
CN116390741A (zh) * 2020-08-19 2023-07-04 西托索尔本茨公司 治疗性和美容性伤口处理

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073778B2 (ja) * 2010-04-01 2017-02-01 サイトソーベンツ・コーポレーション 炎症を治療する方法
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
EP2688602B1 (en) 2011-03-23 2019-11-06 NxStage Medical, Inc. Peritoneal dialysis systems, devices, and methods
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
AU2013282320B2 (en) * 2012-06-29 2017-10-19 Cytosorbents Corporation Methods of using polymers
US10639405B2 (en) 2014-07-22 2020-05-05 Asahi Kasei Medical Co., Ltd. Adsorbent for removing histone and purification device for liquid derived from living organism
RU2018134142A (ru) * 2016-03-08 2020-04-08 Сайтосорбентс Корпорейшн Применение гранулированного сорбента на основе гемосовместимого пористого полимера для удаления молекулярных структур, ассоциированных с патогенами, и молекулярных структур, ассоциированных с повреждениями
RU2018146119A (ru) 2016-05-26 2020-06-26 Сайтосорбентс Корпорейшн Использование гемосовместимого сорбента из пористых полимерных шариков для удаления вызывающих эндотоксикоз молекул
WO2018237375A1 (en) 2017-06-24 2018-12-27 Nxstage Medical, Inc. Peritoneal dialysis fluid preparation and/or treatment devices methods and systems
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物
US20190262526A1 (en) 2018-02-28 2019-08-29 Nxstage Medical, Inc. Fluid Preparation and Treatment Devices Methods and Systems
WO2021034773A1 (en) * 2019-08-16 2021-02-25 Cytosorbents Corporation Methods for improving bone fracture healing
WO2021063708A1 (en) 2019-09-30 2021-04-08 Hemotune Ag Assembly for extracorporeal treatment of body fluids
CA3237831A1 (en) * 2021-11-29 2023-06-01 Cytosorbents Corporation Improved cancer immunotherapy treatments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119576A1 (en) * 2006-11-20 2008-05-22 Wei-Tai Young Size-selective hemoperfusion polymeric adsorbents
US20080138434A1 (en) * 1997-07-30 2008-06-12 Medasorb Corporation Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20100074954A1 (en) * 2002-11-01 2010-03-25 Kureha Chemical Industries Co., Ltd. Adsorbent for oral administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213165B (en) * 1993-05-11 1997-02-28 Bot Process to prepare biopolymers with detoxicating activity
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US20020197250A1 (en) 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
EP1044066A1 (en) 1998-01-06 2000-10-18 Cerus Corporation Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US20020197252A1 (en) 2001-04-10 2002-12-26 Renal Tech International Selective adsorption devices and systems
KR100680449B1 (ko) * 2002-11-01 2007-02-08 가부시키가이샤 쿠레하 경구투여용 흡착제
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
AU2005295708A1 (en) * 2004-10-13 2006-04-27 Relypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
EP1865982A1 (en) 2005-04-06 2007-12-19 Bioartificial Gel Technologies Inc. Hydrogel composition for modulation of topical inflammatory response
EP1842545A1 (en) * 2006-04-04 2007-10-10 Marinomed Biotechnologie GmbH Anti-inflammatory polymer
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
CN101307149B (zh) 2008-05-30 2011-06-01 珠海健帆生物科技股份有限公司 一种医用吸附剂载体的制备方法
MX2011003569A (es) * 2008-10-02 2011-06-09 Univ Pittsburgh Administracion de un polimero adsorbente para el tratamiento de inflamacion sistemica.
US8923172B2 (en) * 2009-08-24 2014-12-30 Qualcomm Incorporated Deterministic backoff channel access
JP6073778B2 (ja) * 2010-04-01 2017-02-01 サイトソーベンツ・コーポレーション 炎症を治療する方法
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138434A1 (en) * 1997-07-30 2008-06-12 Medasorb Corporation Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20100074954A1 (en) * 2002-11-01 2010-03-25 Kureha Chemical Industries Co., Ltd. Adsorbent for oral administration
US20080119576A1 (en) * 2006-11-20 2008-05-22 Wei-Tai Young Size-selective hemoperfusion polymeric adsorbents

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794197A (zh) * 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
US10314859B2 (en) 2014-10-02 2019-06-11 Cytosorbents Corporation Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
CN110662590A (zh) * 2017-05-23 2020-01-07 西托索尔本茨公司 治疗创伤性脑损伤的方法
US12076474B2 (en) 2017-05-23 2024-09-03 Cytosorbents, Inc. Method of treating traumatic brain injury
CN113365642A (zh) * 2018-11-16 2021-09-07 希玛奈克斯特股份有限公司 用于控制炎症患者中不良事件的方法
US12447177B2 (en) 2018-11-16 2025-10-21 Hemanext Inc. Methods for managing adverse events in patients with inflammation
CN115768459A (zh) * 2020-04-14 2023-03-07 西托索尔本茨公司 通过免疫调节治疗改善免疫应答和减少免疫麻痹
CN116390741A (zh) * 2020-08-19 2023-07-04 西托索尔本茨公司 治疗性和美容性伤口处理

Also Published As

Publication number Publication date
US9717755B2 (en) 2017-08-01
US20130195792A1 (en) 2013-08-01
JP2013523772A (ja) 2013-06-17
CA2795177A1 (en) 2011-10-06
EP2552459A1 (en) 2013-02-06
JP2016175914A (ja) 2016-10-06
JP6073778B2 (ja) 2017-02-01
US20180311273A1 (en) 2018-11-01
US10946040B2 (en) 2021-03-16
MX342421B (es) 2016-09-28
WO2011123767A1 (en) 2011-10-06
AU2011234978B2 (en) 2016-03-17
EP2552459A4 (en) 2013-12-25
US20160279163A1 (en) 2016-09-29
US11058715B2 (en) 2021-07-13
ES2686545T3 (es) 2018-10-18
US10967001B2 (en) 2021-04-06
US10034894B2 (en) 2018-07-31
AU2011234978A1 (en) 2012-10-18
EP2552459B1 (en) 2018-07-18
CA2795177C (en) 2018-07-03
MX2012011305A (es) 2013-01-29
EP3384916A1 (en) 2018-10-10
CN107260755A (zh) 2017-10-20
US20170296574A1 (en) 2017-10-19
US20210330697A1 (en) 2021-10-28
US20190282608A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
US10946040B2 (en) Method of treating inflammation
JP6945607B2 (ja) ポリマーの使用法
US9603807B2 (en) Enteral administration of sorbent polymer for treatment and prophylaxis of inflammation
JP2013523772A5 (https=)
US20150335763A1 (en) Hmgb1-binding beads and uses thereof
CN110662590B (zh) 治疗创伤性脑损伤的方法
JP2020532417A (ja) 体液からの終末糖化産物の削減
JP2004323483A (ja) 炎症性疾患治療剤及び炎症性疾患治療用具

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Chan Phillip P

Inventor after: Young Wei-Tai

Inventor after: Capponi Vincent J

Inventor after: Golobish Thomas D

Inventor after: Barlett Robert H

Inventor after: Ali Humayra Begum

Inventor before: Chan Phillip P

Inventor before: Young Wei-Tai

Inventor before: Capponi Vincent J

Inventor before: Golobish Thomas D

Inventor before: Barlett Robert H

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: PHILLIP P. CHAN YOUNG WEI-TAI VINCENT J. CAPPONI THOMAS D. GOLOBISH ROBERT H. BARLETT TO: PHILLIP P. CHAN YOUNG WEI-TAI VINCENT J. CAPPONI THOMAS D. GOLOBISH ROBERT H. BARLETT ALI HUMAYRA BEGUM

RJ01 Rejection of invention patent application after publication

Application publication date: 20130410

RJ01 Rejection of invention patent application after publication